Showing results (511-520 of 733) with videos related to
Sort By:
Pageof 74
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.Cancer Research|April 15, 2022
Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic VulnerabilitiesMaryam Yousefi, Gábor Boross, Carly Weiss, et al.Nature Genetics|September 19, 2022
The evolutionary dynamics of extrachromosomal DNA in human cancersJoshua T Lange, John C Rose, Celine Y Chen, et al.Nature Medicine|May 29, 2020
Geospatial immune variability illuminates differential evolution of lung adenocarcinomaKhalid AbdulJabbar, Shan E Ahmed Raza, Rachel Rosenthal, et al.Biorxiv : the Preprint Server for Biology|January 3, 2024
Imaging the master regulator of the antioxidant response in non-small cell lung cancer with positron emission tomographyHannah E Greenwood, Richard S Edwards, Will E Tyrrell, et al.BMC Cancer|November 16, 2019
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah L Buckley, Fiona J Collinson, Gemma Ainsworth, et al.European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyViktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.The Lancet. Oncology|February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialReinhard Dummer, Jan C Brase, James Garrett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic MelanomaYibing Yan, Matthew J Wongchenko, Caroline Robert, et al.Pageof 74